PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 356.37 ▼ -9.26 (-2.53%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | REGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -6.63 | -1.78% | 365.63 | 373.09 | 362.89 | 373.09 | 372.26 | 18:53:07 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 356.02 | 356.71 | 0.69 | 0.19% | 1 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 15,245 | 988,068 | $ 366.23 | $ 361,862,406 | 817,151 | 271.37 - 445.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:55:16 | average | 4,819 | $ 365.63 | USD |
Regeneron Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 40.14B | 109.80M | $ 2.44B | 21.30 | 19.70 | 108.64M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 5.00 | 1.10% |
Regeneron Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/09/2019 | 17:01 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 12/08/2019 | 09:00 | PR Newswire (US) | First Clinical Data for REGN5458 (BCMAxCD3) Show Positive.. |
| 12/05/2019 | 09:40 | Dow Jones News | Regeneron Reports Positive Phase 2 Data for Pozelimab in PNH |
| 12/05/2019 | 07:00 | PR Newswire (US) | Regeneron Announces Positive Topline Phase 2 Data with.. |
| 12/02/2019 | 16:03 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/27/2019 | 17:29 | Dow Jones News | Early Drug Treatment Sharply Reduces Deaths From Ebola |
| 11/27/2019 | 17:00 | PR Newswire (US) | New England Journal of Medicine Publishes Results of Ebola.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 368.18 | 373.73 | 362.89 | 369.07 | 629,466 | -2.55 | -0.69% |
| 1 Month | 340.34 | 373.73 | 337.03 | 355.70 | 763,832 | 25.29 | 7.43% |
| 3 Months | 285.555 | 373.73 | 271.37 | 319.84 | 730,578 | 80.08 | 28.04% |
| 6 Months | 306.54 | 373.73 | 271.37 | 310.02 | 729,169 | 59.09 | 19.28% |
| 1 Year | 374.52 | 445.00 | 271.37 | 341.80 | 742,706 | -8.89 | -2.37% |
| 3 Years | 371.13 | 543.5518 | 271.37 | 372.73 | 803,809 | -5.50 | -1.48% |
| 5 Years | 428.27 | 605.9299 | 271.37 | 400.24 | 794,346 | -62.64 | -14.63% |
Regeneron Pharmaceuticals Description
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer. |
